CY1113212T1 - Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 11-βητα υδροξυλ στεροειδους - Google Patents

Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 11-βητα υδροξυλ στεροειδους

Info

Publication number
CY1113212T1
CY1113212T1 CY20121100974T CY121100974T CY1113212T1 CY 1113212 T1 CY1113212 T1 CY 1113212T1 CY 20121100974 T CY20121100974 T CY 20121100974T CY 121100974 T CY121100974 T CY 121100974T CY 1113212 T1 CY1113212 T1 CY 1113212T1
Authority
CY
Cyprus
Prior art keywords
type
compounds
spiracycular
hydroxyl steroid
beta hydroxyl
Prior art date
Application number
CY20121100974T
Other languages
English (en)
Inventor
Wenqing Yao
Jincong Zhuo
Colin Zhang
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113212(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of CY1113212T1 publication Critical patent/CY1113212T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε συγκεκριμένες σπειροκυκλικές ενώσεις που είναι αναστολείς αφυδρογονάσης τύπου 1 11-υδροξύλ στεροειδούς (11 HSD1), συνθέσεις που περιέχουν αυτές και μεθόδους χρήσης αυτών για την θεραπεία διαβήτη, παχυσαρκίας και άλλων ασθενειών.
CY20121100974T 2007-06-21 2012-10-17 Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 11-βητα υδροξυλ στεροειδους CY1113212T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94548707P 2007-06-21 2007-06-21
EP08771573.6A EP2173750B9 (en) 2007-06-21 2008-06-20 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1

Publications (1)

Publication Number Publication Date
CY1113212T1 true CY1113212T1 (el) 2016-04-13

Family

ID=39731144

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100974T CY1113212T1 (el) 2007-06-21 2012-10-17 Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 11-βητα υδροξυλ στεροειδους
CY20151100167T CY1116029T1 (el) 2007-06-21 2015-02-18 Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 του 11-βητα υδροξυλ στεροειδους

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20151100167T CY1116029T1 (el) 2007-06-21 2015-02-18 Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 του 11-βητα υδροξυλ στεροειδους

Country Status (31)

Country Link
US (4) US8278318B2 (el)
EP (3) EP2540723B8 (el)
JP (2) JP5364702B2 (el)
KR (1) KR101554471B1 (el)
CN (1) CN101815716B (el)
AR (1) AR067090A1 (el)
AU (1) AU2008265656B2 (el)
BR (1) BRPI0812904A2 (el)
CA (1) CA2691150C (el)
CL (1) CL2008001839A1 (el)
CO (1) CO6150151A2 (el)
CR (1) CR11183A (el)
CY (2) CY1113212T1 (el)
DK (2) DK2173750T3 (el)
EA (1) EA016017B1 (el)
EC (1) ECSP109844A (el)
ES (2) ES2531056T3 (el)
GE (1) GEP20135754B (el)
HK (2) HK1143156A1 (el)
HR (2) HRP20120772T1 (el)
IL (1) IL202842A (el)
MX (1) MX2009014274A (el)
NZ (1) NZ582524A (el)
PL (2) PL2173750T3 (el)
PT (2) PT2173750E (el)
RS (2) RS53839B1 (el)
SI (2) SI2173750T1 (el)
TW (1) TWI428340B (el)
UA (1) UA98651C2 (el)
WO (1) WO2008157752A1 (el)
ZA (1) ZA201000233B (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
WO2006002361A2 (en) * 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
CA2589565A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
EP1758582A4 (en) * 2004-06-24 2008-01-09 Incyte Corp AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICAL PRODUCTS
NZ551603A (en) * 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
CA2575561A1 (en) * 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals
US8110581B2 (en) * 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
WO2007101270A1 (en) * 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
ES2533263T3 (es) 2006-04-21 2015-04-08 Eli Lilly And Company Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
US7820659B2 (en) 2006-04-21 2010-10-26 Eli Lilly And Company Cyclohexylimidiazole lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1
CN101541747B (zh) 2006-04-21 2012-11-14 伊莱利利公司 作为11-β-羟基甾族化合物脱氢酶1的抑制剂的联苯基酰胺内酰胺衍生物
PL2029529T3 (pl) 2006-04-24 2010-11-30 Lilly Co Eli PODSTAWIONE PIROLIDYNONY JAKO INHIBITORY DEHYDROGENAZY 11-ß-HYDROKSYSTEROIDOWEJ TYPU 1
SI2049475T1 (sl) 2006-04-24 2012-04-30 Lilly Co Eli Pirolidinoni substituirani s cikloheksilom kot inhibitorji 11-betahidroksisteroid dehidrogenaze 1
DK2021336T3 (da) 2006-04-24 2010-09-13 Lilly Co Eli 11-beta-hydroxysteroid-dehydrogenase-1-inhibitorer
SI2021337T1 (sl) 2006-04-25 2010-05-31 Lilly Co Eli Inhibitorji beta hidroksisteroidne dehidrogenaze
WO2007127763A2 (en) 2006-04-25 2007-11-08 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EA016360B1 (ru) 2006-04-25 2012-04-30 Эли Лилли Энд Компани Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1, фармацевтическая композиция на их основе и их применение
MX2008013844A (es) 2006-04-28 2008-11-10 Lilly Co Eli Pirrolidinonas substituidas con pieridinilo como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1.
US7838544B2 (en) * 2006-05-17 2010-11-23 Incyte Corporation Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
LT3105226T (lt) 2014-02-13 2019-11-11 Incyte Corp Ciklopropilaminai, kaip lsd1 inhibitoriai
PL3105218T3 (pl) 2014-02-13 2020-03-31 Incyte Corporation Cyklopropyloaminy jako inhibitory lsd1
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
PE20190377A1 (es) 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1
US10435841B2 (en) * 2016-05-03 2019-10-08 GranBio Intellectual Property Holdings, LLC Nanocellulose-reinforced corrugated medium
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439606A (en) * 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
US5206240A (en) * 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
US5852029A (en) * 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5102886A (en) 1990-10-12 1992-04-07 American Home Products Corporation 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones and analogs thereof useful as aldose reductase inhibitors
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2705343B1 (fr) * 1993-05-17 1995-07-21 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.
FR2724656B1 (fr) * 1994-09-15 1996-12-13 Adir Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
CA2233204A1 (en) 1995-09-29 1997-04-03 Joseph A. Jakubowski Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
AU1244001A (en) 1999-10-27 2001-05-08 Cor Therapeutics, Inc. Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
CN1246321C (zh) * 1999-12-03 2006-03-22 小野药品工业株式会社 三氮杂螺[5,5]十一烷衍生物和含其作为活性成分的药物组合物
IL153231A0 (en) 2000-06-28 2003-07-06 Smithkline Beecham Plc Wet milling process
US7294637B2 (en) * 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
US7365205B2 (en) * 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
US6547958B1 (en) * 2001-07-13 2003-04-15 Chevron U.S.A. Inc. Hydrocarbon conversion using zeolite SSZ-59
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
US6911452B2 (en) 2001-12-28 2005-06-28 Acadia Pharmaceuticals Inc. Spiroazacyclic compounds as monoamine receptor modulators
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
GB0213715D0 (en) * 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
WO2004035581A1 (ja) * 2002-10-18 2004-04-29 Ono Pharmaceutical Co., Ltd. スピロ複素環誘導体化合物およびその化合物を有効成分とする薬剤
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
ATE467616T1 (de) 2003-04-11 2010-05-15 High Point Pharmaceuticals Llc Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
WO2005047286A1 (ja) 2003-11-13 2005-05-26 Ono Pharmaceutical Co., Ltd. スピロ複素環化合物
WO2005060963A1 (en) 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
AU2004309419A1 (en) 2003-12-23 2005-07-14 Arena Pharmaceuticals, Inc. Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
CA2558211C (en) 2004-03-03 2013-09-03 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CA2565843A1 (en) 2004-05-06 2005-11-17 Pfizer Inc. Novel compounds of proline and morpholine derivatives
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
CA2589565A1 (en) 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
US20050288317A1 (en) 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
EP1758582A4 (en) 2004-06-24 2008-01-09 Incyte Corp AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICAL PRODUCTS
WO2006002361A2 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
NZ551603A (en) 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
JP2008504276A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
CA2571361C (en) 2004-06-28 2011-07-26 F. Hoffmann-La Roche Ag Pyrimidine derivatives as 11beta-hsd1 inhibitors
CA2575561A1 (en) 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals
DE602005012292D1 (de) 2004-09-29 2009-02-26 Hoffmann La Roche Indozolonderivate als 11b-hsd1-inhibitoren
US7745427B2 (en) 2004-10-22 2010-06-29 Merck Sharp & Dohme Corp. CGRP receptor antagonists
GEP20125565B (en) 2004-11-10 2012-07-10 Incyte Corp Lactam compounds and their pharmaceutical use
EP1815265A2 (en) * 2004-11-12 2007-08-08 U-NAV Microelectronics Corporation Automatic mode setting and power ramp compensator for system power on conditions
CN101103016A (zh) 2004-11-18 2008-01-09 因塞特公司 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法
WO2006074330A2 (en) * 2005-01-05 2006-07-13 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
CN101133026B (zh) * 2005-03-03 2011-07-06 霍夫曼-拉罗奇有限公司 作为治疗Ⅱ型糖尿病用的11β-羟基类固醇脱氢酶抑制剂的1-磺酰基-哌啶-3-羧酸酰胺衍生物
US20070066584A1 (en) * 2005-09-21 2007-03-22 Wenqing Yao Amido compounds and their use as pharmaceuticals
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
TW200804382A (en) * 2005-12-05 2008-01-16 Incyte Corp Lactam compounds and methods of using the same
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20070197530A1 (en) * 2006-01-31 2007-08-23 Yun-Long Li Amido compounds and their use as pharmaceuticals
WO2007101270A1 (en) * 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007103719A2 (en) * 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
CA2649677A1 (en) * 2006-05-01 2007-11-15 Incyte Corporation Tetrasubstituted ureas as modulators of 11-.beta. hydroxyl steroid dehydrogenase type 1
US7838544B2 (en) * 2006-05-17 2010-11-23 Incyte Corporation Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same
MX2008016426A (es) 2006-07-05 2009-01-19 Hoffmann La Roche Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
KR20110079776A (ko) 2006-10-19 2011-07-07 에프. 호프만-라 로슈 아게 당뇨병을 위한 11베타-에이치에스디1 억제제로서의 이미다졸론 및 이미다졸리딘온 유도체
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.

Also Published As

Publication number Publication date
TWI428340B (zh) 2014-03-01
MX2009014274A (es) 2010-03-25
CN101815716B (zh) 2012-12-26
AR067090A1 (es) 2009-09-30
RS52519B9 (sr) 2020-12-31
JP2010530893A (ja) 2010-09-16
CR11183A (es) 2010-02-16
NZ582524A (en) 2012-05-25
US9371323B2 (en) 2016-06-21
RS52519B (en) 2013-04-30
KR101554471B1 (ko) 2015-09-30
DK2173750T3 (da) 2012-11-19
BRPI0812904A2 (pt) 2014-12-09
PT2173750E (pt) 2012-10-11
JP2014015463A (ja) 2014-01-30
HRP20120772T1 (hr) 2012-10-31
US20150210692A1 (en) 2015-07-30
CA2691150C (en) 2015-11-24
KR20100045440A (ko) 2010-05-03
EA016017B1 (ru) 2012-01-30
ECSP109844A (es) 2010-02-26
WO2008157752A1 (en) 2008-12-24
US20130018068A1 (en) 2013-01-17
EA201070039A1 (ru) 2010-06-30
CL2008001839A1 (es) 2009-01-16
EP2540723B8 (en) 2015-01-28
TW200909431A (en) 2009-03-01
GEP20135754B (en) 2013-02-25
US9006260B2 (en) 2015-04-14
EP2918586A1 (en) 2015-09-16
SI2540723T1 (sl) 2015-04-30
US20080318991A1 (en) 2008-12-25
JP5364702B2 (ja) 2013-12-11
UA98651C2 (ru) 2012-06-11
PT2540723E (pt) 2015-03-06
JP5730956B2 (ja) 2015-06-10
AU2008265656B2 (en) 2014-05-29
HRP20150197T1 (en) 2015-03-27
EP2173750A1 (en) 2010-04-14
US9873698B2 (en) 2018-01-23
US8278318B2 (en) 2012-10-02
CY1116029T1 (el) 2017-01-25
EP2173750B1 (en) 2012-08-01
PL2173750T3 (pl) 2012-12-31
AU2008265656A1 (en) 2008-12-24
EP2540723A1 (en) 2013-01-02
IL202842A (en) 2014-11-30
ES2390937T3 (es) 2012-11-19
SI2173750T1 (sl) 2012-11-30
ZA201000233B (en) 2016-08-31
EP2173750B9 (en) 2017-04-05
HK1180325A1 (zh) 2013-10-18
EP2540723B1 (en) 2014-11-26
IL202842A0 (en) 2010-06-30
RS53839B1 (en) 2015-06-30
DK2540723T3 (en) 2015-01-19
CO6150151A2 (es) 2010-04-20
CA2691150A1 (en) 2008-12-24
PL2540723T3 (pl) 2015-07-31
HK1143156A1 (en) 2010-12-24
ES2531056T3 (es) 2015-03-10
CN101815716A (zh) 2010-08-25
US20160280708A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
CY1113212T1 (el) Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 11-βητα υδροξυλ στεροειδους
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
CY1119660T1 (el) Antibakthpiakh απο toy στοματος συνθεση
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
CY1118680T1 (el) Φαρμακευτικη συνθεση
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
CY1112497T1 (el) Παραγωγα διοξα-δικυκλο[3.2.1]οκταν-2,3,4-τριολης
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
CY1109696T1 (el) Υποκατεστημενα παραγωγα πυριδινυλιου και πυριμιδινυλιου ως διαμορφωτες του μεταβολισμου και η θεραπεια των σχετικων με αυτον διαταραχων
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
BRPI0512856A (pt) métodos e reagentes para o tratamento de distúrbios metabólicos
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
MA32467B1 (fr) Derives de piperidinyle agonistes de gpcr
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
TW200640863A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
JO2645B1 (en) Vehicles
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
EA201170795A1 (ru) Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола
JO2747B1 (en) Vehicles